ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ÉúÃü¿ÆѧѧԺ²ÜÓÀ³¤½ÌÊÚÑо¿ÍŶÓÔÚH7N9Á÷¸Ð²¡¶¾¹ãÆ×ÒßÃçÑо¿ÁìÓòÈ¡µÃÍ»ÆÆÐÔÏ£Íû

ÔĶÁÁ¿£º

¿ËÈÕ£¬£¬ £¬ÉúÃü¿ÆѧѧԺÓк¦ÉúÎï¿ØÖÆÓë×ÊԴʹÓùú¼ÒÖصãʵÑéÊÒ²ÜÓÀ³¤½ÌÊÚÍŶÓÔÚ¹ú¼Ê¿¹²¡¶¾È¨ÍþÆÚ¿¯¡¶Antiviral Research¡·ÉϽÒÏþÁËÎÊÌâΪ¡°A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice¡±µÄÑо¿ÂÛÎÄ£¬£¬ £¬±¨µÀÁËÒ»ÖÖ¶ÔѪÄýËØÂÑ°× £¨Hemagglutinin£¬£¬ £¬HA£©¾ÙÐнṹÉè¼ÆµÄH7N9Á÷¸Ð²¡¶¾È«²¡¶¾Ãð»îÒßÃ磬£¬ £¬²¢ÇÒ֤ʵÕâÖÖÈ«²¡¶¾Ãð»îÒßÃç¿ÉÒԴ̼¤»úÌ屬·¢H7N9ÑÇÐÍÄÚ¹ãÆ×½»Ö¯ÃâÒß·´Ó³ºÍ½»Ö¯ÑÚ»¤ ¡£¡£²ÜÓÀ³¤½ÌÊÚΪ±¾ÎÄͨѶ×÷Õߣ¬£¬ £¬²©Ê¿Ñо¿ÉúÍõÑóΪ±¾ÎĵÚÒ»×÷Õß ¡£¡£

×Ô2013Äê3ÔÂÎÒ¹úÊ״ᨵÀH7N9Á÷¸Ð²¡¶¾Ñ¬È¾ÈËÒÔÀ´£¬£¬ £¬H7N9Á÷¸Ð²¡¶¾ÒѾ­ÂÄÀúÁË5²¨Ê¢ÐУ¬£¬ £¬Ñ¬È¾²¡Àý1364Àý£¨×èÖ¹2017Äê4ÔÂ1ÈÕ£©£¬£¬ £¬éæÃüÂÊ´ï30% ¡£¡£H7N9Á÷¸Ð²¡¶¾²»µ«¾ßÓÐDZÔÚ´óÊ¢ÐеÄÍþв£¬£¬ £¬Ò²¶ÔÑøÇÝÒµÔì³ÉÁËÖØ´óµÄËðʧ ¡£¡£¸úÆäËûÁ÷¸Ð²¡¶¾Ò»Ñù£¬£¬ £¬H7N9Á÷¸Ð²¡¶¾±äÒìÊ®·ÖѸËÙ£¬£¬ £¬ÒѾ­ÐγÉÁ˶à¸ö»ùÒòÐÍ£¬£¬ £¬Òò´ËÑÐÖƾßÓйãÆ×½»Ö¯ÑÚ»¤Ð§¹ûµÄH7N9Á÷¸Ð²¡¶¾ÒßÃçÊ®·ÖÐëÒª ¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ÖØ×éH7N9Á÷¸Ð²¡¶¾µÄÕü¾È

²ÜÓÀ³¤½ÌÊÚÍŶÓ֮ǰµÄÑо¿Ö¤ÊµH3ÑÇÐÍHAÂѰ׿çĤÇø£¨Transmembrane domain£¬£¬ £¬TM£©ÓëHAÂÑ°×ÎȹÌÐÔ¡¢¡¢¡¢HAÂÑ°×½»Ö¯ÃâÒßÔ­ÐÔ¹ØϵÇ×½ü£¬£¬ £¬Í¨¹ýHA¿çĤÇøÖû»Õ½ÂÔ¿ÉÒÔÌá¸ßÈý¾Û»¯H1¡¢¡¢¡¢H5ºÍH9ÑÇÐÍHAÂÑ°×µÄÑÇÐͼ佻֯ÑÚ»¤Á¦ ¡£¡£ÔÚH7N9¹ãÆ×ÒßÃçµÄÑо¿ÖУ¬£¬ £¬¸ÃÍŶӽ«H7N9Á÷¸Ð²¡¶¾HAÂÑ°×TMÖû»ÎªH3ÑÇÐÍHA TM£¬£¬ £¬²¢Í¨¹ý·´ÏòÒÅ´«ÊÖÒÕÕü¾È³ö°üÀ¨TMÖû»µÄÖØ×éH7N9Á÷¸Ð²¡¶¾ ¡£¡£ÔÚСÊó¶¯ÎïÄ£×ÓÖУ¬£¬ £¬ÖØ×鲡¶¾ÖƱ¸µÄÈ«²¡¶¾Ãð»îÒßÃçÄܹ»ÓÕµ¼»úÌ屬·¢Õë¶Ô²î±ð·ÖÖ§¶¾Ö꿹ԭµÄ¸ü¸ßµÄHI¿¹Ìå¡¢¡¢¡¢HAÌØÒìÐÔIgG¿¹Ìå¡¢¡¢¡¢HAÌØÒìÐÔIFN-¦Ãϸ°ûÒò×Ó ¡£¡£¸ÃÒßÃçÄܹ»¶ÔСÊóͬԴ»òÒìÔ´H7N9²¡¶¾¹¥¶¾ÌṩÍêÈ«ÑÚ»¤£¬£¬ £¬¾­ÓÉÃâÒßµÄСÊóÔÚ¹¥¶¾ºó¼ì²â²»µ½·Î²¡¶¾µÎ¶È¡¢¡¢¡¢ÎÞÏÔ×ŷβ¿²¡±äºÍÑ×Ö¢·´Ó³ ¡£¡£

²ÜÓÀ³¤½ÌÊÚÍŶӺã¾Ã¾ÙÐж¯Îﲡ¶¾Ñ§Ñо¿£¬£¬ £¬ÏȺó»ñµÃ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢¡¢¡¢863ÏîÄ¿¡¢¡¢¡¢¹ú¼ÒÖصãÑз¢ÍýÏëÏîÄ¿¡¢¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðµÈ¿ÆÑÐÏîÄ¿µÄ×ÊÖú£¬£¬ £¬½ÒÏþSCIÂÛÎÄ30Óàƪ ¡£¡£ÏÖÔÚ¸ÃÍŶÓÖÂÁ¦ÓÚÁ÷¸Ð²¡¶¾·À¿Ø¡¢¡¢¡¢¹Ú×´²¡¶¾£¨ÖíÊ¢ÐÐÐÔ¸¹Ðº²¡¶¾PEDV¡¢¡¢¡¢¼¦Ñ¬È¾ÐÔÖ§Æø¹ÜÑײ¡¶¾IBV£©ÒÅ´«ÑÝ»¯ºÍÃâÒßÌÓÒÝ»úÖÆÑо¿£¬£¬ £¬ÒÑ»ñµÃ¶àÏîÑо¿Ð§¹û ¡£¡£

¡¾ÍøÕ¾µØͼ¡¿